BioSpace News Archive

IMR-687 is designed as an oral therapy for once-daily dosing to address both the underlying red and white blood cell pathologies associated with SCD.

Additionally, the Company has granted the underwriters an option to purchase up to an additional 441,176 shares of its common stock, at the price to the public.

Newly reported data to be presented in the oral presentation will include pooled results, as well as individual results.

The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.

This sterile-packed innovative system adds to the original implant design also available, while providing internal fixation via a dual threaded construct which is inserted between the proximal and middle phalanges so that the opposing threads fixate within the phalangeal canals of the toe to compress the proximal interphalangeal (PIP) joint.

Test rapidly detects 47 antimicrobial resistance markers directly from urine and bacterial isolates.

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call:

SpinalCyte’s Phase 1/2 trial is the first allogeneic use of fibroblasts outside of skin conditions.

BC Platforms today announces that Pfizer Finland will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases.

BioNano Genomics today announced the global commercial launch of new chemistry for sequence motif labeling called Direct Label and Stain.